Literature DB >> 24406933

Collateral damage.

Robert E W Hancock1.   

Abstract

Mesh：

Substances：

Year:  2014        PMID： 24406933     DOI： 10.1038/nbt.2779

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN： 1087-0156            Impact factor:   54.908


× No keyword cloud information.
  8 in total

Review 1.  Collateral sensitivity as a strategy against cancer multidrug resistance.

Authors:  Kristen M Pluchino; Matthew D Hall; Andrew S Goldsborough; Richard Callaghan; Michael M Gottesman
Journal:  Drug Resist Updat       Date:  2012-04-06       Impact factor: 18.500

Review 2.  Modulating immunity as a therapy for bacterial infections.

Authors:  Robert E W Hancock; Anastasia Nijnik; Dana J Philpott
Journal:  Nat Rev Microbiol       Date:  2012-03-16       Impact factor: 60.633

Review 3.  Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America.

Authors:  Helen W Boucher; George H Talbot; John S Bradley; John E Edwards; David Gilbert; Louis B Rice; Michael Scheld; Brad Spellberg; John Bartlett
Journal:  Clin Infect Dis       Date:  2009-01-01       Impact factor: 9.079

Review 4.  Antibiotic adjuvants: multicomponent anti-infective strategies.

Authors:  Lindsay Kalan; Gerard D Wright
Journal:  Expert Rev Mol Med       Date:  2011-02-23       Impact factor: 5.600

Review 5.  Creeping baselines and adaptive resistance to antibiotics.

Authors:  Lucía Fernández; Elena B M Breidenstein; Robert E W Hancock
Journal:  Drug Resist Updat       Date:  2011-02-01       Impact factor: 18.500

6.  Use of collateral sensitivity networks to design drug cycling protocols that avoid resistance development.

Authors:  Lejla Imamovic; Morten O A Sommer
Journal:  Sci Transl Med       Date:  2013-09-25       Impact factor: 17.956

Review 7.  Antimicrobial stewardship: a review of prospective audit and feedback systems and an objective evaluation of outcomes.

Authors:  Gladys W Chung; Jia En Wu; Chay Leng Yeo; Douglas Chan; Li Yang Hsu
Journal:  Virulence       Date:  2013-01-09       Impact factor: 5.882

Review 8.  Antivirulence therapy for animal production: filling an arsenal with novel weapons for sustainable disease control.

Authors:  Tom Defoirdt
Journal:  PLoS Pathog       Date:  2013-10-10       Impact factor: 6.823
  8 in total
  6 in total

1.  Screen of FDA-approved drug library identifies maprotiline, an antibiofilm and antivirulence compound with QseC sensor-kinase dependent activity in Francisella novicida.

Authors:  Scott N Dean; Monique L van Hoek
Journal:  Virulence       Date:  2015       Impact factor: 5.882

2.  Indole contributes to tetracycline resistance via the outer membrane protein OmpN in Vibrio splendidus.

Authors:  Shanshan Zhang; Yina Shao; Xuelin Zhao; Chenghua Li; Ming Guo; Zhimeng Lv; Weiwei Zhang
Journal:  World J Microbiol Biotechnol       Date:  2020-02-22       Impact factor: 3.312

Review 3.  Collateral sensitivity of antibiotic-resistant microbes.

Authors:  Csaba Pál; Balázs Papp; Viktória Lázár
Journal:  Trends Microbiol       Date:  2015-03-25       Impact factor: 17.079

4.  Assessment of Phenotype Microarray plates for rapid and high-throughput analysis of collateral sensitivity networks.

Authors:  Elsie J Dunkley; James D Chalmers; Stephanie Cho; Thomas J Finn; Wayne M Patrick
Journal:  PLoS One       Date:  2019-12-18       Impact factor: 3.240

5.  Where Electrostatics Matter: Bacterial Surface Neutralization and Membrane Disruption by Antimicrobial Peptides SAAP-148 and OP-145.

Authors:  Djenana Vejzovic; Paulina Piller; Robert A Cordfunke; Jan W Drijfhout; Tobias Eisenberg; Karl Lohner; Nermina Malanovic
Journal:  Biomolecules       Date:  2022-09-07

6.  Convergent phenotypic evolution towards fosfomycin collateral sensitivity of Pseudomonas aeruginosa antibiotic-resistant mutants.

Authors:  Pablo Laborda; José L Martínez; Sara Hernando-Amado
Journal:  Microb Biotechnol       Date:  2021-05-07       Impact factor: 5.813
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.